Hydroxychloroquine: Drug overview, approved indications and role in treating COVID-19

Hydroxychloroquine: Drug overview, approved indications and role in treating COVID-19

“Hydroxychloroquine drug insight”
Hydroxychloroquine got recommended to be used against malaria in 1955 and is categorized as the safest and most effective medicines needed in a health system.
Dozens of clinical studies are ongoing to study the efficacy and safety of the drug in fighting COVID-19. Hydroxychloroquine and chloroquine are under clinical evaluations for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection, & treatment of adult patients with mild, moderate, and severe COVID-19.

DelveInsight’s ‘Hydroxychloroquine – Drug Insights 2020’ report delivers an in-depth understanding of the hydroxychloroquine, its various marketed products and their details across the world, approvals, withdrawals (if any), patent details, Global API (Hydroxychloroquine) manufacturers (The United States, Europe, India and China), competitive landscape (marketed as well as emerging therapies), SWOT analysis along with the historical and forecasted global sales for all the marketed hydroxychloroquine formulations.

Region: Global

Hydroxychloroquine overview

Hydroxychloroquine got recommended to be used against malaria in 1955 and is categorized as the safest and most effective medicines needed in a health system.

The drug is approved for indications including uncomplicated malaria due to Plasmodium falciparum, P. malariae, P. ovale, and P. vivax; chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and acute and chronic rheumatoid arthritis in adult.

Visit to know more.

Dosage Forms and Administration

  • One Plaquenil tablet contains 200 mg of hydroxychloroquine sulfate, which is equivalent to 155 mg base.
  • Take Plaquenil with a meal or a glass of milk.

Hydroxychloroquine and COVID-19

On March 28, 2020, FDA issued an emergency use authorization (EUA) that permits chloroquine and hydroxychloroquine to be distributed from the Strategic National Stockpile (SNS) to public health authorities to facilitate availability of the drugs during the COVID-19 pandemic for use only in hospitalized adults and adolescents weighing ≥50 kg for whom a clinical trial is not available or participation not feasible.

Dozens of clinical studies are ongoing to study the efficacy and safety of the drug in fighting COVID-19. Hydroxychloroquine and chloroquine are under clinical evaluations for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection, & treatment of adult patients with mild, moderate, and severe COVID-19.

Request for sample pages

Report Highlights

  • 11-Year Forecast of Hydroxychloroquine marketed products
  • Global Coverage
  • Hydroxychloroquine and COVID-19
  • SWOT Analysis
  • Global API Manufacturers (The United States, Europe, China and India)
  • Market Competitors
  • Competitive Landscape for emerging drugs

 

Table of contents

  1. Report Introduction
  2. Hydroxychloroquine (Plaquenil)
  3. Product Overview
  4. Product Description
  5. Mechanism of action
  6. 6.Dosage and Administration
  7. 7.Research and Development
  8. 8.Product Developmental Activities
  9. Product Details
  10. Hydroxychloroquine Global Sales Assessment
  11. 11.Historical and Forecasted Global Sales
  12. Patent Details
  13. Global API Manufacturers
  14. Market Competitors
  15. Competitive Landscape (Emerging Therapies)
  16. SWOT Analysis
  17. Appendix

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/